Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy
Mengjiao Zhou,Minjian Yuan,Meng Zhang,Chenyi Lei,Omer Aras,Xiaohong Zhang,Feifei An
DOI: https://doi.org/10.1016/j.ejmech.2021.113825
IF: 7.088
2021-12-01
European Journal of Medicinal Chemistry
Abstract:Histone deacetylases (HDACs) play important roles in regulating gene expression of tumorigenesis and tumor maintenance, and they have been considered as key targets in cancer therapy. As an novel category of antitumor agents, the histone deacetylase inhibitors (HDACis) can induce cell cycle arrest, apoptosis, and differentiation in cancer cells, and then combat cancer. Despite the treatment of certain cancers have been approved, the therapeutic efficacy of HDACis with solid tumors is always unsatisfactory and the drug resistance may occur. To enhance the therapeutic efficacy and reverse acquired drug resistance, numerous combination therapies involving HDACis in synergy with other antitumor therapies have been studied. In this review, we have made a brief classification of HDACs. Moreover, the antitumor mechanism of the HDACis for targeting key cellular processes of cancers (cell cycle, apoptosis, angiogenesis, DNA repair, and immune response) has been summarized. In addition, we have also outlined the major developments of other antitumor therapies in combination with HDACis, including chemotherapy, radiotherapy, phototherapy, targeted therapy, and immunotherapy. Finally, we have discussed the current state and challenges of HDACis-drugs combinations in future clinical trials, with the aim of optimizing the antitumor effect of such combinations.
chemistry, medicinal